Last reviewed · How we verify

NCT05721963

Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients

Status unknown Last updated 10 February 2023
What this trial tests

trial testing No interventions. in Cholangiocarcinoma in 30 participants. Status unknown.

Timeline
1 February 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 February 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of proteomics approaches on resected lymph node samples in evaluating lymph node metastasis status in cholangiocarcinoma patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No interventions.

Trials testing the same drug.

Other recruiting trials for Cholangiocarcinoma

Currently open trials in the same condition.

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05721963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing